Clazakizumab: Difference between revisions
It is made using yeast cells rather than the standard Chinese hamster ovary cells.<ref |
Anypodetos (talk | contribs) m Updated source |
||
| Line 2: | Line 2: | ||
| type = mab |
| type = mab |
||
| image = |
| image = |
||
| source = |
| source = zu |
||
| target = [[interleukin-6|IL-6]] |
| target = [[interleukin-6|IL-6]] |
||
| CAS_number = |
| CAS_number = |
||
Revision as of 10:08, 14 March 2010
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | IL-6 |
| Clinical data | |
| Routes of administration | infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
ALD518 a humanized monoclonal antibody against interleukin-6. It is an investigational drug for cancer and rheumatoid arthritis due to its anti-inflamatory properties.
The relatively long half life of about 30 days should allow less frequent and subcutaneous injections.[1]
It is made using yeast cells rather than the standard Chinese hamster ovary cells.[1]
Clinical trials
Cancer
A phase I clinical trial showed ALD518 was well tolerated and could reverse fatigue in cancer patients.[2]
A phase II trial for advanced cancer is due to end in Oct 2009.[3]
Rheumatoid arthritis
The Phase IIa trial for rheumatoid arthritis[4] has completed with promising results leading to a licencing deal allowing phase III trials.[5]
References
- ^ a b http://www.xconomy.com/seattle/2008/09/18/alder-sets-stage-for-showdown-with-roche-with-fast-follower-antibody-drug-strategy/
- ^ http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32916 "A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer." 2009
- ^ http://www.boliven.com/clinical_trial/NCT00866970 Phase II: "Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-Related Fatigue and Cachexia"
- ^ http://clinicaltrials.gov/ct2/show/NCT00867516
- ^ http://www.smartbrief.com/news/aanp/industryBW-detail.jsp?id=9279E59B-9E2A-4823-9476-17782B175A34 "Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic" 10 Nov 2009
External links
See also
- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |